Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Invion ( (AU:IVX) ) is now available.
Invion Limited has announced a fully underwritten, non-renounceable entitlement offer to raise approximately $1 million. The offer is available only to eligible shareholders in Australia, New Zealand, and Hong Kong, and involves issuing new options with specific exercise prices and expiry dates. This move is part of Invion’s strategy to strengthen its financial position and support its ongoing projects in the life-science sector.
More about Invion
Invion is a life-science company focused on the research and development of Photosoft™ technology, which is used for treating various cancers, atherosclerosis, and infectious diseases. The company holds exclusive rights to this technology in Australia, New Zealand, Hong Kong, and other parts of Asia Pacific, excluding certain regions. Invion’s research and clinical trials are funded by RMW Cho Group Limited, and it is listed on the ASX.
YTD Price Performance: -55.36%
Average Trading Volume: 101,227
Technical Sentiment Signal: Sell
Current Market Cap: A$10.59M
For a thorough assessment of IVX stock, go to TipRanks’ Stock Analysis page.